Latest News

GlaxoSmithKline and Sanofi to donate 200mln doses of COVID-19 vaccine to COVAX


GlaxoSmithKline (LON:GSK) and French partner Sanofi have agreed to supply 200mln of a COVID-19 vaccine they are developing to COVAX, the global body designed to guarantee equitable access to coronavirus treatments. 

The two companies have signed a Statement of Intent with Gavi, the legal administrator of the COVAX Facility to deliver the vaccine once it has received regulatory approval.

Sanofi and GSK initiated a Phase 1/2 study for the vaccine on September 3, 2020, with a total of 440 subjects enrolled, and anticipate first results in early December 2020, to support the initiation of a pivotal Phase 3 study before the end of the year.

In a statement, Roger Connor, president of GSK Vaccines said: “Since we started working on the development of COVID-19 vaccines, GSK has pledged to make them available to people around the world.

“We are proud to be working with Sanofi to make this adjuvanted recombinant protein-based vaccine available to the countries signed up to the COVAX Facility as soon as possible – this has the potential to be a significant contribution to the global fight against COVID-19.”

The COVAX Facility is part of COVAX, a global collaboration of governments, global health organisations, businesses and philanthropic organizations working to accelerate development, production, and equitable access to COVID-19 vaccines. COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO.

More than 180 countries have signed up to the COVAX Facility.

Owner of Woolworths’ trademark quashes rumour of store’s return following Twitter storm

Previous article

FTSE 100 sinks as Wall Street opens in the red

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News